Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-IKZF3 Antibody (R2N91)

Catalog #:   RHN53001 Specific References (35) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: IHC, WB
Accession: Q9UKT9
Overview

Catalog No.

RHN53001

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

IHC: 1:50-1:100, WB: 1:500-1:1000

Target

Ikaros family zinc finger protein 3, IKZF3, ZNFN1A3, Zinc finger protein Aiolos

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9UKT9

Applications

IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R2N91

Data Image
  • Immunohistochemical
    Immunohistochemistry analysis of paraffin-embedded Human tonsil using IKZF3 antibody.High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.
  • Western blot
    Western blot analysis of IKZF3 in HL-60, U251 lysates using IKZF3 antibody.
References

Sequence variants influencing the regulation of serum IgG subclass levels., PMID:39277589

Transcriptional function of E2A, Ebf1, Pax5, Ikaros and Aiolos analyzed by in vivo acute protein degradation in early B cell development., PMID:39179932

Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide., PMID:39054911

Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens., PMID:37945755

IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target., PMID:36180600

Drug resistance and minimal residual disease in multiple myeloma., PMID:35582527

Comprehensive Analysis of lncRNA Expression Profile and the Potential Role of ENST00000604491 in Graves' Disease., PMID:35509980

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial., PMID:34530760

Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus., PMID:33727237

A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation., PMID:33689703

Urinary Cell Transcriptome Profiling and Identification of ITM2A, SLAMF6, and IKZF3 as Biomarkers of Acute Rejection in Human Kidney Allografts., PMID:32766436

Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide., PMID:32591583

Rapid and deep-scale ubiquitylation profiling for biology and translational research., PMID:31953384

Genetic Variants Predisposing Most Strongly to Type 1 Diabetes Diagnosed Under Age 7 Years Lie Near Candidate Genes That Function in the Immune System and in Pancreatic β-Cells., PMID:31558544

Immunomodulatory drugs in the treatment of multiple myeloma., PMID:31187860

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos., PMID:30228232

Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus., PMID:29945920

Loss of B-Cell Anergy in Type 1 Diabetes Is Associated With High-Risk HLA and Non-HLA Disease Susceptibility Alleles., PMID:29343548

Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity., PMID:28848067

Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups., PMID:28584254

Genetic variants associated with rheumatoid arthritis patients and serotypes in European populations., PMID:26939566

Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells., PMID:26823144

PDK1 regulates VDJ recombination, cell-cycle exit and survival during B-cell development., PMID:23463102

Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation., PMID:23303821

Lacking of Aiolos accelerates pre-mature B cell apoptosis mediated by BCR signaling through elevation in cytochrome c release., PMID:19427336

CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche., PMID:19228948

Silencing and nuclear repositioning of the lambda5 gene locus at the pre-B cell stage requires Aiolos and OBF-1., PMID:18974788

Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development., PMID:17971486

Ikaros DNA-binding proteins as integral components of B cell developmental-stage-specific regulatory circuits., PMID:17363301

Pax5--a critical inhibitor of plasma cell fate., PMID:16918686

Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity., PMID:14718515

Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice., PMID:12574333

The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21., PMID:11371362

Aiolos regulates B cell activation and maturation to effector state., PMID:9806640

Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitors., PMID:9560339

Datasheet

Document Download

Anti-IKZF3 Antibody (R2N91).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-IKZF3 Antibody (R2N91) [RHN53001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only